Latest Breaking News On - டேவிட் கிளேர் - Page 6 : comparemela.com

Bio-Techne Announces Commercial Release of Abby Automated Western System for Simple Western and Introduces Stellar Modules for Jess

MINNEAPOLIS, April 8, 2021 /PRNewswire/ Â Bio-Techne Corporation (NASDAQ:TECH) today announced that ProteinSimple, a Bio-Techne brand, released Abby, its next generation chemiluminescence system that automates traditional Western blotting.Â This latest addition to the Simple Western product family offers picogram-level sensitivity through chemiluminescence detection along with the ability to perform sequential immunoassays using RePlexâ¢.Â Abby is accompanied by the latest version of Compass software for Simple Western that adds to its publication-ready data analysis tools extensive lane view annotation capabilities that save hours typically spent editing in other programs.Â In addition, ProteinSimple has announced the pending release of Stellarâ¢ NIR and IR modules for Jessâ¢ which will set a new industry standard for fluorescence Western blotting sensitivity.

Dave eansorDavid clairSteve crouseBio techne analytical solutions divisionInvestor relations corporate developmentBio techne protein sciences segmentBio techne corporationSimple westernVice presidentGeneral managerAnalytical solutionsProprietary replexProtein sciencesSenior directorInvestor relationsடேவிட் கிளேர்

Bio-Techne To Host Conference Call On May 6, 2021 To Announce Third Quarter 2021 Financial Results

A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 13718437. The replay will be available from 11:00 a.m. CDT on Thursday, May 6, 2021 until 11:00 p.m. CDT on Sunday, June 6, 2021. Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. Bio-Techne s product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laborat

David clairProtein sciences segmentInvestor relations corporate developmentBio techne corporationTechne corporationProtein sciencesSenior directorInvestor relationsNasdaq nms techMinnesotaMidwestUnited states of americaNorth americaடேவிட் கிளேர்ப்ரோடீந் அறிவியல் பிரிவுமுதலீட்டாளர் உறவுகள் பெருநிறுவன வளர்ச்சி

Bio-Techne Completes Acquisition of Asuragen, Inc.

Share this article Share this article MINNEAPOLIS, April 6, 2021 /PRNewswire/ Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed the acquisition of Asuragen, Inc. The transaction included initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones. The Asuragen acquisition adds a leading portfolio of best-in-class molecular diagnostic and research products, including genetic screening and oncology testing kits, molecular controls, a Good Manufacturing Practice (GMP)-compliant 50,000 square foot manufacturing facility and a CLIA-certified laboratory, plus a team with deep expertise navigating products through the global diagnostic regulatory environment. Bio-Techne sees multiple growth synergies as a result of this acquisition, including capabilities in productizing lab-developed tests and commercializing innovative molecular products for broader market adoption. Bio

David clairExchange commissionPrnewswire bio techne corporationAmerican college of obstetriciansCorporate developmentAsuragen incBio techne corporationTechne corporationGood manufacturing practiceAmerican collegeLooking statementsPrivate securities litigation reformSenior directorInvestor relationsடேவிட் கிளேர்பரிமாற்றம் தரகு

Bio-Techne Announces Receipt of COVID-19 Innovation Award from CiteAb

Bio-Techne Announces Receipt of COVID-19 Innovation Award from CiteAb
grandrapidsmn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from grandrapidsmn.com Daily Mail and Mail on Sunday newspapers.

Kantaro biosciencesChuck kummethDavid clairCorporate developmentMount sinai health systemElla cytokine storm panelBio techne corporationEmergency use authorizationNovus biologicalsChief executiveSenior directorInvestor relationsடேவிட் கிளேர்பெருநிறுவன வளர்ச்சிஏற்ற சினை ஆரோக்கியம் அமைப்புஉயிர் தொழில்நுட்பம் நிறுவனம்

Bio-Techne's Exosome Diagnostics Laboratory Announces CE-IVD Certification For ExoDx Prostate Test

Bio-Techne's Exosome Diagnostics Laboratory Announces CE-IVD Certification For ExoDx Prostate Test
mesabitribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mesabitribune.com Daily Mail and Mail on Sunday newspapers.

MunichBayernGermanyUnited kingdomChuck kummethDavid clairAlexander kretschmerPrnewswire bio techne corporationInvestor relations corporate developmentBio techne corporationTechne corporationExosome diagnosticsAssistant professorLudwig maximilians university munichChief executive officerExodx prostate